• SEPTEMBER 22, 2000

A strong dose from Pfizer

Despite apprehensions about the intentions of the management, after the setting up of a 100% subsidiary, Pfizer continues to report healthy growth rates.

(Rs m) 3QFY00 3QFY01 Change
Sales 885 1,003 13.4%
Other Income 17 21 19.9%
Expenditure 727 793 9.1%
Operating Profit (EBDIT) 158 210  
Operating Profit Margin (%) 17.8% 20.9%  
Interest 3 1 -66.7%
Depreciation 18 13 -31.1%
Profit before Tax 154 217 41.1%
Other Adjustments      
Tax 55 88  
Profit after Tax/(Loss) 99 129 30.7%
Net profit margin (%) 11.2% 12.9%  
Earnings per share* 16.84 22.01  

The company has delivered a 30% increase in post–tax profits in the third quarter of the current year, despite Becousules (its B–complex vitamin) being brought under price control. (Becousules contributes around 20% to the company’s turnover and the National Pharmaceutical Pricing Authority has reduced its prices by 30% in the current year.)

The company’s topline grew by 13% over the corresponding period of last year. The stock quotes at Rs 606, which implies an earning multiple of 27.5 times.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407